887594-13-0

Basic information

• Product Name: 3-(2-CYANO-ACETYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER
• Synonyms: 3-(2-CYANO-ACETYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER;1-Boc-3-(2-cyano-acetyl)-...;1-Boc-3-(2-cyano-acetyl)-azetidine;tert-butyl 3-cyanoacetyl-1-azetidinecarboxylate;tert-Butyl 3-(2-cyanoacetyl)azetidine-1-carboxylate
• CAS NO: 887594-13-0
• Molecular Formula: C11H16N2O3
• Molecular Weight: 224.26
• Mol File: 887594-13-0.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(2-CYANO-ACETYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-CYANO-ACETYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(887594-13-0)
• EPA Substance Registry System: 3-(2-CYANO-ACETYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER(887594-13-0)

Safety Data

• Hazardous Substances Data: 887594-13-0(Hazardous Substances Data)

Usage

General Description

3-(2-cyano-acetyl)-azetidine-1-carboxylic acid tert-butyl ester is a chemical compound with the molecular formula C11H15N3O3. It is an ester derivative of azetidine-1-carboxylic acid, which is a naturally occurring amino acid. 3-(2-CYANO-ACETYL)-AZETIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER is commonly used as a building block in organic synthesis to create various pharmaceuticals and agrochemicals. It is also known for its potential anticonvulsant and sedative properties, making it a subject of interest in medicinal chemistry research. The tert-butyl ester group provides stability and protection to the carboxylic acid functionality, making it a versatile intermediate in chemical synthesis.

Upstream product

• 610791-05-4 azetidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-methyl ester 
• 75-05-8 acetonitrile 
• 142253-55-2 1-(t-butyloxycarbonyl)-azetidine-3-carboxylic acid 

Downstream Products

• 1346674-11-0 tert-butyl 3-(3-amino-1H-pyrazol-5-yl)azetidine-1-carboxylate 
• 1346674-11-0 tert-butyl 3-(5-amino-1H-pyrazol-3-yl)azetidine-1-carboxylate 

Relevant articles and documents

NOVEL PYRIDONE CARBOXYLIC ACID DERIVATIVE OR SALT THEREOF

It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells. The present invention provides a pyridone carboxylic acid derivative represented by the following formula (1) or a salt thereof wherein R1 represents a hydrogen atom, a halogen atom or the like; R2 represents a hydrogen atom, a halogen atom or the like; R3 to R6 each represent a hydrogen atom or the like; R7 represents a hydrogen atom or the like; R8 represents a hydrogen atom, a halogen atom, the following formula (a) (wherein Ra1 and Ra2 each represent a hydrogen atom, a hydroxy group, an optionally substituted lower alkyl group or the like) or the like, or R7 and R8 together represent —N—OR10 (wherein R10 represents a hydrogen atom, an optionally substituted lower alkyl group, or an aralkyl group), or R7 and R8 form an optionally substituted 4- to 6-membered saturated hetero ring together with the adjacent carbon atom, or the like; R9 represents a hydrogen atom or the like; X represents a nitrogen atom or the like; and Y represents a nitrogen atom or the like.

HETEROCYCLIC COMPOUND

The present invention provides an agent for the prophylaxis or treatment of autoimmune diseases (e.g., psoriasis, rheumatoid arthritis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus etc.) and the like, which has a superior Tyk2 inhibitory action. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS

The present invention provides for compounds of Formula (I) and various embodiments thereof, and compositions comprising compounds of Formula (I) and various embodiments thereof. (I) In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6 and R7 have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula (I) as DLK inhibitors and for treating neurodegeneration diseases and disorders.